CIK 0001738021 · Non-accelerated filer<br>Smaller reporting company
Compass Therapeutics, Inc.
Sign in to watch- Ticker
- CMPX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-500-8099
- Business address
- 80 GUEST STREET, BOSTON, MA, 02135
- Former names
- Olivia Ventures, Inc.
- Open-market buys, last 90 days
- $21,250
- in 2 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$21,250. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-02-17 | Kalled Susan Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2021-11-16 | Schuetz Thomas J. Chief Executive Officer | Grant or award | +600,000 | 5,125,467 | ||
| 2021-11-16 | Bisker-Leib Vered Chief Operating Officer | Grant or award | +600,000 | 1,113,401 | ||
| 2021-11-04 | GORDON CARL L Director | Purchase | +1,785,715 | $3.50 | $6.3M | 14,500,119 |
| 2021-11-04 | GORDON CARL L Director | Purchase | +3,571,428 | $3.50 | $12.5M | 3,571,428 |
| 2021-11-04 | ORBIMED ADVISORS LLC Director | Purchase | +1,785,715 | $3.50 | $6.3M | 14,500,119 |
| 2021-11-04 | ORBIMED ADVISORS LLC Director | Purchase | +3,571,428 | $3.50 | $12.5M | 3,571,428 |
| 2021-06-25 | Toledano Miranda Jayne Director | Other acquisition | +1,791,549 | 1,791,549 | ||
| 2021-06-25 | Toledano Miranda Jayne Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2021-05-03 | Kalled Susan Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +260,000 | 260,000 | ||
| 2021-02-09 | Schuetz Thomas J. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +700,000 | 700,000 | ||
| 2021-02-09 | Bisker-Leib Vered President & COO | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2020-12-22 | Schuetz Thomas J. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2020-09-10 | Kaplan Brett Director | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2020-08-06 | SQUINTO STEPHEN P Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2020-08-06 | Bisker-Leib Vered Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +600,000 | 600,000 | ||
| 2020-08-06 | Schuetz Thomas J. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2020-06-19 | Sunderland Julie Director | Purchase | +289,118 | $5.00 | $1.4M | 2,502,025 |
| 2020-06-19 | Schuetz Thomas J. Chief Executive Officer | Purchase | +97,431 | $5.00 | $487K | 4,525,467 |
| 2020-06-19 | Ferneau Philip Director | Purchase | +64,066 | $5.00 | $320K | 2,348,976 |
Page 7 of 8 · 143 trades